Skip to content
Q3 2019 Fabege AB Earnings Call...
Despite grounding some of their most expensive assets for months, most of the world’s airlines — except for perhaps Ryanair — have been diplomatic in their treatment of Boeing over Max problems. The manufacturer, they say, is a “trusted partner,” and if any disagreements arise, they promise to deal with them privately. Might that soon […]...
(Bloomberg) -- A look at the price action and you’d be forgiven for thinking all was well in emerging markets.Far from it.While indexes of stocks, bonds and currencies hover around their strongest levels since early August, political crises from Ecuador and Argentina to Turkey, South Africa and -- most recently -- Chile and Lebanon are reminding investors of the risk of getting too deep in some of the highest-yielding markets.For David Levy, chairman of the Jerome Levy Forecasting Center, the combination of the clamor for higher returns and ballooning debt levels in the developing world is reminiscent of the U.S. housing market before the global financial crisis.“This cycle’s asset bubble is the emerging-market sector,” Levy said. “In the next recession there will be serious problems for emerging markets.”PODCAST: How Exploding Private Sector Balance Sheets Have Changed Recessions As We Know ThemThe turmoil was underscored on Monday when Chile, which has Latin...
Swiss drugmaker Novartis on Tuesday boosted its full-year targets, with sales now expected to grow at a high single-digit percentage rate and core operating income now seen growing at a mid- to high-teen rate. The therapy's regulatory review in Europe and Japan was delayed, with an anticipated decision in the first quarter of 2020 in Europe and an expected decision in Japan in the first half of 2020....
Swiss drugmaker Novartis boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world's most expensive one-time treatment. CEO Vas Narasimhan's bet on the potential cure for spinal muscular atrophy (SMA) has drawn scrutiny, initially due to its $2.1 million (£1.6 million) price and since August over a data manipulation scandal that has prompted a U.S. Food and Drug Administration (FDA) investigation. "We're very pleased with the uptake," Narasimhan told reporters on a call....
Sunrise Communications Group called off a shareholders meeting set for Wednesday to approve a rights issue needed to complete its 6.3 billion Swiss franc ($6.39 billion) acquisition of Liberty Global's UPC business. Freenet, which is Sunrise's biggest shareholder, and other investors had opposed the 2.8 billion franc rights issue, forcing Sunrise into the climbdown. It said it cancelled the extraordinary general meeting (EGM) with Liberty Global's consent....
Sunrise Communications Group bowed to investor pressure on Tuesday and scrapped its 6.3 billion Swiss franc ($6.39 billion) acquisition of Liberty Global's Swiss cable business UPC. The number two Swiss telecommunications group had battled to save the deal in the face of opposition from its biggest shareholder, Germany's Freenet, which holds 25% of its stock, and activist investors including Axxion and AOC....
